MAA
LFCR icon

Mraz Amerine & Associates’s Lifecore Biomedical LFCR Stock Holding History

Mraz Amerine & Associates’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.5K Buy
17,625
+2,000
+13% +$10.1K 0.01% 191
2026
Q1 		$58.1K Buy
+15,625
New +$108K 0.01% 185

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Mraz Amerine & Associates's LFCR Position: Q2 2026 in Review

Mraz Amerine & Associates increased its Lifecore Biomedical (LFCR) stake by 13% in Q2 2026, buying an estimated $10.1K and bringing the position to 17,625 shares worth $92.5K. The position accounts for 0.01% of the portfolio, ranked #191.

Mraz Amerine & Associates first reported a position in LFCR in Q1 2026 and has held it in 2 quarters since. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Mraz Amerine & Associates held 17,625 shares of Lifecore Biomedical worth $92.5K as of Q2 2026.
  • Mraz Amerine & Associates bought 2,000 Lifecore Biomedical shares in Q2 2026, an estimated $10.1K.
  • Lifecore Biomedical made up 0.01% of Mraz Amerine & Associates's portfolio in Q2 2026, its #191 holding.
  • Mraz Amerine & Associates first reported a position in Lifecore Biomedical in Q1 2026 and has held it in 2 quarters since.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Mraz Amerine & Associates's 13F filing for Q2 2026, filed 16 Jul 2026.